---
layout: post
title: "Considerations for Complying With 21 CFR 211.110; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:49:31 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-31356
original_published: 2025-01-06 00:00:00 +0000
significance: 8.00
---

# Considerations for Complying With 21 CFR 211.110; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** January 06, 2025 00:00 UTC
**Document Number:** 2024-31356

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Considerations for Complying With 21 CFR 211.110." This guidance, when finalized, will describe considerations for complying with the requirements for ensuring batch uniformity and drug product integrity. In addition, this guidance discusses related quality considerations for drug products that are manufactured using advanced manufacturing. FDA is committed to supporting and enabling pharmaceutical innovation and modernization as part of the Agency's mission to protect and promote the public health. FDA encourages industry representatives and manufactures who are interested in using innovative control strategies to contact the Agency.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/01/06/2024-31356/considerations-for-complying-with-21-cfr-211110-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2024-31356

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
